On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulin ...
Colorectal cancer is the third most common cancer in the United States. Although screening has led to a decrease in incidence ...
After decades of decline, rates of rectal cancer have risen by about 1 percent each year from 2018 to 2022. Rectal cancer, which originates in the last 12 to 15 centimeters of the large intestine, now ...
The gut microbiome at time of surgery may significantly impact recurrence of colorectal cancer.An analysis of nearly 300 ...
Shannon Ivey was 42 and a single mom when she was diagnosed with Stage 3 rectal cancer. She reveals the symptoms she mistook ...
Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...
Gastrointestinal cancers are expected to double globally by 2050, according to a new multi-institutional study co-led by Los Angeles-based Cedars-Sinai, among others. The authors’ projections are ...
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided ...
17h
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results